Related Experiment Video
Updated: Jul 20, 2026
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma
Adaleta Mulaomerović1, Alma Halilbasić, Elmir Cickusić
1Medical Faculty, University of Tuzla, Bosnia and Herzegovina.
Insights
Cystatin C levels are elevated in non-Hodgkin B-cell lymphoma patients. This biomarker shows potential for detecting relapses in lymphoma patients.
Area of Science:
- Biochemistry
- Oncology
- Immunology
Background:
- Non-Hodgkin B-cell lymphoma is a significant hematologic malignancy.
- Early detection and monitoring of disease progression are crucial for patient outcomes.
- Cystatin C, a cysteine protease inhibitor, has been investigated for various clinical applications.
Observation:
- Serum cystatin C concentrations were significantly higher in patients with non-Hodgkin B-cell lymphoma compared to healthy controls.
- Elevated cystatin C levels were observed in both treated and untreated patients.
- The highest cystatin C levels were found in patients experiencing a relapse of the lymphoma.
Findings:
- Enzyme-linked immunosorbent assay (ELISA) revealed significantly increased cystatin C in lymphoma patients (p<0.00001).
- Immunofluorescence and confocal microscopy identified immature dendritic cells as a primary source of cystatin C in affected lymph nodes.
- Cystatin C concentration correlates with disease status, particularly relapse.
Implications:
- Cystatin C may serve as a novel, non-invasive biomarker for monitoring non-Hodgkin B-cell lymphoma.
- This finding could lead to improved relapse detection and personalized treatment strategies.
- Further research is warranted to validate cystatin C as a reliable marker in clinical practice.
Abstract:
The concentration of cysteine protease inhibitor cystatin C was determined in sera from 59 patients with non-Hodgkin B-cell lymphoma using ELISA. The sera from 43 age and sex matched healthy blood donors served as controls. Cystatin C was significantly increased in sera of patients without therapy (mean 1136+/-SE 105.7ng/ml, p=0.00001) and with therapy (mean 1073+/-52ng/ml, p=0.001) compared to controls (mean 819+/-28ng/ml). The highest levels were determined in sera of patients with a relapse (mean 1680+/-196ng/ml). By using immunofluorescence staining and confocal microscopy we determined immature dendritic cells as a major population of cystatin C positive cells in affected lymph nodes. Our study reports for the first time that cystatin C is a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma.
